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Introduction. The advertising of food supplements on various media channels or in special-
ty stores with natural products and other places, as well as the lack of informative and edu-
cational programs for the population upon side effects and the interaction of food supple-
ments with food and drugs, have led to the development of uncontrolled marketing of these 
products.  
Material and methods. PubMed, ResearchGate and EUR-Lex databases were analyzed 
during 2015-2021, based on search criteria based on: adverse reactions, ingredient new 
food, food supplements, algorithms.  
Results. Certain dietary supplements can cause multiple side effects, such as: impaired 
platelet function by decreased platelet aggregation, gastrointestinal side effects (diarrhea, 
vomiting), decreased wound healing/epithelialization, bacterial or fungal sepsis, most 
common in patients older. Herbal resources such as Aloe vera, Matricaria recutita, Taraxa-
cum officinale and others, can cause dermatological side effects and inhibit the elimination 
of dermatological drugs metabolised by cytochrome P-450 (e.g. terbinafine). Matricaria 
recutita, Allium sativum, Mentha piperita L. and others, inhibit the enzyme CYP2C9. Another 
enzyme with a role in the metabolism of dermatological drugs and which is inhibited by 
plant resources is CYP3A4. 
Conclusions. It is imperative to legislate the reporting of adverse reactions caused by food 







ALGORITMI POSIBILI PENTRU DETERMINAREA REACȚIILOR ADVERSE CAUZATE DE  
SUPLIMENTELE ALIMENTARE ÎN ROMÂNIA 
Introducere. Promovarea suplimentelor alimentare în diverse surse media sau de către 
unele magazine, în special de cele specializate în comercializarea produselor naturale, pre-
cum și lipsa programelor informative și educaționale pentru populație cu privire la efectele 
secundare și interacțiunea suplimentelor alimentare cu alimentele și medicamentele, au dus 
la dezvoltarea comercializării necontrolate a acestor produse.  
Material si metode. Bazele de date PubMed, Research Gate și EUR-Lex au fost analizate în 
perioada 2015-2021, pe baza criteriilor de căutare: reacții adverse, ingrediente alimentare 
noi, suplimente alimentare, algoritmi.  
Rezultate. Anumite suplimente alimentare pot provoca efecte secundare multiple, cum ar fi: 
afectarea funcției trombocitelor prin scăderea agregării plachetare, efecte secundare gas-
trointestinale (diaree, vărsături), scăderea vindecării/epitelizării rănilor, sepsis bacterian 
sau fungic, atestate cel mai frecvent la pacienții cu vârstă înaintată. Resursele vegetale pre-
cum Aloe vera, Matricaria recutita, Taraxacum officinale și altele, pot provoca reacții ad-
verse dermatologice și inhiba eliminarea medicamentelor dermatologice metabolizate de 
citocromul P-450 (de exemplu terbinafină). Matricaria recutita, Allium sativum, Mentha 
piperita L. și altele, inhibă enzima CYP2C9. O altă enzimă cu rol în metabolismul medica-
mentelor dermatologice și care este inhibată de resursele vegetale este CYP3A4. 
Concluzii. Este imperativ să se reglementeze raportarea reacțiilor adverse cauzate de su-
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Advertising of food supplements on various me-
dia channels or in specialty stores with natural 
products, as well as the lack of information and 
educational programs of the population, on ad-
verse reactions and interaction of food supple-
ments with food and drugs, have led to uncon-
trolled development of marketing these prod-
ucts. 
Although in the US, the FDA (Food and Drug Ad-
ministration) only authorizes food and drugs, the 
1994 Dietary Supplement Health and Education 
Act (DSHEA) monitors the side effects (SE) of 
post-market food supplements (1). Under this 
law, food supplements are orally ingested foods 
that include botanical products (such as herbal 
remedies) and non-botanical substances, such as 
minerals, amino acids, vitamins and microbial 
products, and traditional cultural remedies, in-
cluding Asian plants (2). Although the prohibi-
tion on the statement that "food supplement (FS) 
may be used for the treatment or prevention of a 
disease" is valid in Romania, in the USA, the men-
tion regarding general well-being and health is 
allowed provided that on the packaging/label is 
"This statement has not been evaluated by the 
FDA. This product is not intended to diagnose, 
treat, cure or prevent any disease" (1).  
SE has been found and reported in vitamin food 
supplements:  
• doses higher than 500 mg/day pyridoxine 
(vitamin B6) – photosensitivity, neurotoxicity, 
• chronic sensory polyneuropathy associated 
with pyridoxine,  
• bleeding associated with antiplatelet action at 
doses 800-1200 mg/day,  
• diarrhea, weakness, blurred vision and 
gonadal dysfunction at doses higher than 
1200 mg/day α-tocopherol (vitamin E) and  
• increased recurrence of cancer in the first 3.5 
years (1).  
The "Retinol Efficacy Trial" and "ATBC" studies 
demonstrated the toxicity of β-carotene (vitamin 
A) supplements by significantly increasing the 
risk of lung cancer in male smokers (1). Follow-
ing the study "Teratogenicity of high vitamin A 
intake" (1), researchers Rothman KJ, Moore LL, 
Singer MR et al. suggested the association of die-
tary supplements containing vitamin A with ad-
verse effects on bone health and decreased bone 
density, thus increasing the risk of fracture.  
Side effects have also been found with mineral 
supplements, omega 3/fish oil, soy protein, soy 
protein, plant nutrients, antioxidants, anti-
inflammatory, supplements for weight loss or 
bodybuilding, various botanical supplements (3). 
Multi-skeletal distortion, fatigue, pain and gas-
trointestinal symptoms and hepatic adverse 
events have been reported with the nutraceutical 
ingredient RYR (red yeast rice) at the doses rec-
ommended by EFSA (European Food Safety Au-
thority) (4). 
With the exception of "classic" foods (hazelnuts, 
nuts, eggs, etc.) known to cause certain side ef-
fects such as allergies, the development of the 
food industry has led to the emergence of foods 
eaten especially by teenagers, such as energy 
drinks. Frequent consumption of this type of 
drink (≥7 times a week) was significantly associ-
ated with asthma, allergic rhinitis and atopic 
dermatitis (3), high stress, lack of sleep, poor 
school performance and suicide attempts in Ko-
rean adolescents (5). 
This present research is aimed at displaying the 
algorithms that can be applied to determine ad-
verse reactions caused by the consumption of 
food supplements and foods in Romania, the 
need to initiate a legislative project and its im-
plementation regarding the reporting of these 
adverse reactions and implementation of infor-
mation/education programs on the population 
when consuming these products. The implemen-
tation of the nutrition surveillance system may 
be one of the methods of re-evaluation of food 
additives approved by EFSA and European 
Commission (EC).  
The purpose of this paper was to implement nu-
trivigilence in Romania. 
 
MATERIAL AND METHODS  
The PubMed, ResearchGate and EUR-Lex data-
bases (online portal offering access to EU legisla-
tion) were analyzed during 2015-2021, starting 
from the search criteria like: side effects, new 
food ingredients, supplements food, algorithms. 
Herbal resources that may influence the clear-
ance of dermatological drugs metablized by cy-
tochrome P-450 have been identified (enzymes 
CYP2C9, and CYP3A4). 
 
RESULTS 
Of the total of 5696 European Union Regulations 
and/or Decisions published during this period, 
39 refer to the authorization of novel food ingre-
dients in the European Union, which are pre-
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In addition to the product categories mentioned 
in Table 1, the oil extracted from the microalga 
Schizochytrium sp. (ATCC PTA-9695) may be 
added to dairy products, other than milk-based 
beverages, for cheeses, dairy products, excluding 
beverages or, for cheese-like products, spreada-
ble fat and salad dressings, bakery products 
(bread and buns), sweet biscuits, cereal bars, 
cooking fats, non-alcoholic beverages (including 
similar dairy products and milk-based drinks), 
preparations for infants and preparations for 
young children – used in accordance with Di-
rective 2006/141/EC, cereal-based preparations 
and baby foods for infants and young children, 
including those used in accordance with Di-
rective 2006/125 (8). 
Regarding food supplements, special medical 
foods and foods for use in low-calorie diets listed 
in Table 1, refined Buglossoides arvensis seed oil 
is approved as a novel food ingredient in dairy 
products and the like, beverages, cheese and 
cheeses, butter and other fat and oil emulsions, 
including spreads (not for cooking or frying), 
breakfast cereals (14). 
The European Commission has approved lacto-
N-neotetraose (tab. 1) (16) as a novel food in-
gredient in pasteurized and sterilized milk prod-
ucts (including UHT), non-flavored, non-flavored 
fermented milk products, beverages and other 
products than beverages, flavored fermented 
milk products, including heat-treated products in 
beverages and non-beverages, cereal bars, table-
top sweeteners, infant formulas, as defined in 
Directive 2006/141/EC. 
In vitro and in vivo studies suggest that trans-
resveratrol sulphate may inhibit CYP enzymes in 
humans and may interact with drugs that are 
primarily metabolised by CYP2C9 (22). 
Other authorized uses for yeast beta glycans 
(Saccaromyces cerevisiae) are the following: 
beverages based on fruit juice and/or vegetable 
juice including concentrated and dehydrated 
juice, fruit flavored beverages, powdered form 
for cocoa-based beverages, breakfast cereals, 
breakfast cereals, whole grain breakfast cereals 
(instant hot cooking), cookies, crackers, milk 
drinks, dairy products fermented milk, similar 
dairy products, dehydrated milk/milk powder, 
soups and mixes for soups, chocolate and sweets, 
protein bars and protein powder, jam, marma-
lade and other fruit spreads (25). 
The extended conditions under which taxifolin-
rich extract may be used are the plain yo-
gurt/fruit yoghurt (when used in dairy products, 
taxifolin-rich extract may not replace, in whole 
or in part, any constituent of milk), kefir, sour 
milk, powdered milk, cream, fermented cream, 
cheese, butter, chocolate confectionery, soft 
drinks (28). 
Commercially grown Agaricus bisporus mush-
rooms are subjected to ultraviolet treatment 
after harvest, which results in a vitamin D2 con-
tent of ≤ 10 μg/100 g fresh weight. UVB radia-
tion: a process of radiation in ultraviolet light 
with a wavelength in the range 290-320 nm. Vit-
amin D2 in the finished product: 5-10 μg/100 g 
fresh weight at the end of the shelf life (35). 
The Scientific Opinion issued by EFSA on mon-
acolin K in RYR (36), it has the same structure as 
lovastatin, the active ingredient in several medi-
cines authorized to treat hypercholesterolemia 
in the EU. With the help of the Mintel Global New 
Products (MintelGNPD) database, which lists the 
contents of all product labels containing mon-
acolin K from RYR, 40 products containing mon-
acolin K from RYR were identified and included 
in the category "Vitamins and dietary supple-
ments". Approximately 25% of the total products 
identified provided the daily intake of 10 mg 
monacolin K recommended by EFSA, and only 8 
products were identified as mono-ingredients, 
containing only RYR preparation (36). Although 
studies underlying this scientific opinion have 
shown that monacolin K and lovastatin rapidly 
convert from the lactone form to an identical 
form of hydroxy acid (HA), the latter being re-
sponsible for the inhibition of 3-hydroxy-3. 
Methylglutaryl-coenzyme A (HMG-CoA) enzyme 
reductase involved in cholesterol biosynthesis, 
and the acid form occurs naturally in RYR. The 
bioavailability of lovastatin increases by 30-50% 
when taken as a standard dose. Due to the in-
volvement of the CYP3A4 isoform in its metabo-
lism, there have been found interactions with 
drugs or food ingredients with inhibitors of this 
enzyme, leading to increased plasma statin levels 
and a possible increased risk of toxic effects (36).  
The WHO, FDA, EMA, and ANSES have published 
common side effects for RYR and lovastatin: 
damage to musculoskeletal and connective tis-
sue, liver, nervous system, gastrointestinal tract, 
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The case reports used to carry out the aforemen-
tioned scientific opinion, specified the daily in-
take of monacolin K in which SE (rhab-
domyolysis, hepatitis and skin disorders) oc-
curred was 3 mg/day for a period between 2 
weeks and 1 year (36). 
L-ergothioneine is also accepted as a novel food 
ingredient in the following food categories: non-
alcoholic beverages, milk-based beverages, fresh 
dairy products – maximum 0.040 g/kg (when 
used in dairy products, L-ergothioneine cannot 
replace, in whole or in part, any milk constitu-
ent), cereal bars. The name of the novel food 
mentioned on the label of foods containing it is 
"L-ergothioneine" (39). 
In addition to food supplements, the European 
Commission and EFSA have approved yeast for 
ultraviolet-baked bread (Saccharomyces cere-
visiae) and for the addition of yeast-leavened 
bread and buns, yeast-leavened bakery products, 
fresh or dried pre-packaged yeast for home bak-
ing (41). 
In accordance with Article (5) of Regulation (EU) 
no. 1133/2018 (43), in its opinion, the Authority 
did not confirm the safety of dry aerial parts of 
Hoodia parviflora in food for the uses and use 
levels proposed by the applicant, as consumption 
would exceed the level considered safe (0.134 
mg/kg body weight). However, the Authority 
concluded that the dry aerial parts of Hoodia 
parviflora are safe for adults when added to food 
supplements in a maximum daily dose of 9.4 mg, 
which corresponds to the safe level of consum-
ption of an adult with a body weight of 70 kg. 
In the case of refined shrimp peptic concentrate - 
by enzymatic hydrolysis of shells and heads of 
northern shrimp (Pandalus borealis) (48), ac-
cording to point (13) of Regulation (EU) no. 1633 
of 2018, data from the 90-days oral toxicity 
study served as a basis for assessing the toxicity 
profile of refined shrimp peptide concentrate 
and for establishing the level at which no ad-
verse effects are observed. Data from the study 
evaluating the antihypertensive effects and safe-
ty of the refined peptide concentrate in shrimp in 
healthy subjects with mild to moderate hyper-
tension, as well as data from the parallel double-
blind, placebo-controlled study on the evaluation 
of the antihypertensive effect and safety dietary 
supplement with refined shrimp peptide concen-
trate in the case of healthy individuals with mild 
or moderate hypertension, served as a basis for 
establishing the safety of the novel food for this 
category of consumers.  
Therefore, it is considered that, in the absence of 
data from the unpublished reports of those stud-
ies, it would not have been possible to reach 
these conclusions on the safety of the refined 
shrimp peptide concentrate. In carrying out this 
study, the applicant replied that some Member 
States had objected to the safety of refined 
shrimp peptide concentrate in the case of hypo-, 
normo- and hypertensive consumers given its 
alleged antihypertensive effects, its potential 
side effects related to its presumed ability to 
inhibition of angiotensin converting enzyme 
(ACE) and its potential cardiac effects, and on 
potential drug interactions used in the treatment 
of blood pressure disorders (48). 
Powder with a high content of partially defatted 
chia seed protein (Salvia hispanica) (62), in addi-
tion to food supplements (tab. 1) may also be 
added in unflavored fermented dairy products, 
including unflavored natural sour milk (exclud-
ing sterilized sour milk), untreated after fermen-
tation, non-flavored fermented milk products, 
heat-treated after fermentation, flavored fer-
mented milk products, including heat-treated 
products, confectionery, fruit juices within the 
meaning of Directive 2001/112/EC and vegeta-
ble juices, fruit nectars within the meaning of 
Directive 2001/112/EC and vegetable nectars 
and similar products, flavored beverages. Pow-
der with a high content of partially defatted chia 
seed fibers (Salvia hispanica) is accepted by EF-
SA for addition to confectionery, fruit juices 
within the meaning of Directive 2001/112/EC 
and vegetable juices, fruit nectars within the 
meaning of Directive 2001/112/EC and vegeta-
ble nectars and similar products, flavored bever-
ages (62). 
Given the clinical trials conducted by various 
teams of specialists, EFSA considers that in the 
case of yeast biomass (Yarrowia lipolytica) (72) 
containing selenium, it should be re-evaluated 
(74). 
Probiotics that can cause human sepsis, general-
ly in elderly patients and those suffering from 
chronic diseases, are Lactobacilli (strains of L. 
rhamnosis, due to its high translocation poten-
tial) (77), Lactobacillus sp. bacteremia which is 
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(77) caused by L. rhamnosus, L. casei, L. acidophi-
lus, L. jensenii, L. plantarum and L. paracasei  (77). 
They can cause anaphylactic response in patients 
who have undergone cardiovascular surgery (77) 
or localized infection in diabetes associated with 
old age and liver transplantation (77). 
Thus, for terbinafine (78) which is metabolised 
by the enzyme CYP3A4 and the clearance (or 
intracellular concentration) of this drug may be 
influenced by dietary supplements/other prod-
ucts containing Agaricus blazei Murrill, Aloe vera, 
Artemisia annua, Andrographis paniculata, Matri-
caria recutita, Chrysanthemum morifolium, Vitex 
agnus castus, Taraxacum officinale, Echinacea 
purpurea, Tanacetum parthenium, Zingiber offici-
nale, Allium sativum, Hydrastis Canadensis, Cen-
tella asiatica, Commiphora mukul, Crataegus mo-
nogyna, Cymbopogon citratus ,  Artemisia annua, 
Urtica dioica, Mentha piperita L, 3,3', 4', 5,7-
pentapentahydroxyflavone (quercetin), Monas-
cus purpureus (Red Yeast Rice), Trifolium 
pratense, 3,5, 4'-trihydroxystilbene (resveratrol), 
Rhodiola rosea, Serenoa repens, Glycine max 
(Soy), Turmeric longa (79). 
The CYP2C9 enzyme metabolizes dermatological 
drugs such as voriconazole (80) and can be in-
hibited by dietary supplements/other products 
containing Andrographis paniculata, Sulphydryl  
proteolytic enzyme, cysteine proteinase, Matri-
caria recutita, Harpagophytum procumbens, 
Tanacetum parthenium, Allium sativum, Centella 
asiatica, Cymbopogon citratus (Lemongrass), 
Magnolia officinalis, Urtica dioica, Mentha piperi-
ta L. (Peppermint), Trifolium pratense, 3,5,4'-
trihydroxystilbene (resveratrol), Serenoa repens, 
Eleutherococcus senticosus (79). 
As regarding "Nutrivigilance that is a new activi-
ty referring to dietary supplements" (2), the au-
thors Morgan C, Ghibu S, Juncan AN et al pre-
sented the current use of SE and the interaction 
with drugs of certain substances or herbs, such 
as Aloe Vera, Aristolochic acids/Aristolochia sp, 
Chelidonium majus, Citrus sp, Cytisus sp, Echina-
cea purpurea, Ginkgo biloba, Green tea extract, 
Camellia sinensis, Hypericin St. John’s wort/Hy-
pericum perforatum, Lamiaceae sp. With high 
contents in Rosmarinic acid, Valeriana officinalis, 
etc. 
To establish the severity-causality relationship 
in the case of SA, authors such as Kazuki I, Hiro-
shi Y, Mamoru K et al. (79) propose the use of 
algorithms used in pharmacovigilance, for drug-
induced RA: Naranjo scale, FDA, Kramer scale, 
Liverpol scale, WHO scale. 
Table 4 and Figure 1 show the Naranjo and FDA 
algorithms. 
 
Table 4. Naranjo algorithm (81). 
Nr. 
No 
The question Yes* Not* 
I do not 
know * 
1 Is there a notification about the reaction, on the label or in the package leaflet 
food supplement? 
   
2 Did the side effect occur after taking the food supplement?    
3 Did the adverse reaction improve when the suspected food supplement was 
discontinued? 
   
4 Did the adverse event recur when the food supplement was given?    
5 Are there any causes other than the dietary supplement that could have 
caused side effects? 
   
6 Was the reaction more severe when the dose was increased or less severe 
when the dose was decreased? 
   
7 Did the consumer have a similar adverse reaction to the similar food sup-
plement in the previous exposure? 
   
8 Has the adverse event been confirmed by any objective evidence?    
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Given that new food ingredients can be added to 
food supplements and a wide range of foods, in 
which new food ingredients, the lifestyle of many 
people can be added, there is a risk of reaching 
and/or exceeding the maximum allowable dose 
and challenging AR identified or unidentified up 
to date. A major risk is the large amount of com-
mercial information on the benefits of various 
plant resources, without a possible and scientifi-
cally proven/clinically proven AR and their in-
teraction with food or medicine. 
Nutrivigilence is also important from the per-
spective of CYP's transformation of certain plant 
components into toxic or mutagenic  
substances and reactive, carcinogenic metabo-
lites by 1'-hydroxylation to allylic side chains 
and the bioactivation of alkylbenzenes, such as  
CYP1A1, CYP1A2, and CYP1A2, and by their high 
catalytic capacity they contributed to the meta-
bolic activation of elemicin, by the formation of 
1'-hydroxyelemicine (82). Thus, excessive intake 
of foods and spices containing elemicin can lead 
to cellular toxicity. This is an argument why nu-
trivigilence is important in both the food and 
food supplements, dietetics and nutrition and 
pharmaceutical industries. 
We propose the application of the algorithm 
model for drug-induced RA to food supplements. 
One method of collecting information on possible 
ARs caused by FS is by telephone survey, includ-
ing the following criteria: the substance involved, 
the age of the patient (adult/paediatric), the type 
of ingestion (accidental or intentional), the food 
consumed and their approximate amount, where 
he bought FS (hypermarket, health food store, 
community pharmacy, online pharmacy or vari- 
 
 
I don't know 
 
Was the adverse event confirmed  
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ous websites), the symptoms recorded, evaluat-
ed according to severity and causality. 
Another method of collecting information about 
AR caused by FS are online questionnaires dis-
tributed through social networks, or through 
companies organizing medical events or other-
wise. 
We joined the signal sent by colleagues Morgan 
C, Ghibu S, Juncan AN et al (2) and supported the 
urgent need to legislate the reporting of adverse 
reactions caused by dietary supplements, includ-
ing their interaction with food or medicine. The 
veracity of the practical applicability of the legis-
lation and the existence of an educational pro-
gram of the population, proved that this inter-
vention is not to be null and void. 
We consider that the formation of multidiscipli-
nary teams of regional specialists, as well as  
their cooperation on a regular basis, might have 
a constructive brainstorming for data collection 
(adverse reactions, age, etc.), the database for-
mation and the identification of severity-
causality, which could be a good start for imple-
menting nutrivigilance in Romania. 
Given the mandatory pharmacovigilance process 
in pharmaceutical companies, a similar system of 
nutrivigilance is needed in food and food sup-
plement factories in Romania. The implementa-
tion of the nutrition surveillance system may be 
one of the methods of re-evaluation of food addi-
tives and ingredients approved by the European 
Food Safety Authority (EFSA) and European 
Commission. 
Due to the complexity of nutrivigilence, this arti-
cle has the following weaknesses: the methodol-




1. The formation of territorial teams of specialists and their involvement in risk assessment, 
monitoring and management of unauthorized exposure to food supplements, especially among 
vulnerable population groups, can have a constructive impact on the collection of medical and 
pharmaceutical data (adverse reactions, age, etc.). 
 
2. The formation of a pharmacovigilence database and the identification of the causality of the 
reported side effects could be a good start in implementing nutrivigilence in Romania.  
 
3. We recommend conducting a pilot study in Romania and possibly in collaborat ion with col-
leagues from the Republic of Moldova, to test the two algorithms and adapt to the conditions in 
this area. 
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